HPAPi2022 — SMi’s 6th Annual Highly Potent Active Pharmaceutical Ingredients

The Global High Potency API/HPAPI Market is projected to reach 37 billion USD by 2027, growing at an ever-increasing CAGR of 8.43%. The expanding production of high potency APIs, along with the increase in associated toxicities, are driving requirements for more effective containment solutions and much-needed guidelines to ensure worker safety. SMi Group are delighted to announce the 6th Annual Highly Potent Active Pharmaceutical Ingredients Conference will be taking place on 9th – 10th May 2022 in London, UK. The conference will encompass the critical topics including risk assessment, occupational toxicology, engineering controls for containment, facility design, and the impact of pharmaceutical manufacture on the environment.

Topics: EHS, Environmental Health and Safety, CDMO, Contract Development and Manufacturing Organisation, GMP, Good Manufacturing Practice, OEL, Occupational Exposure Limits, PPE, Personal protective equipment, HBEL, Health based Exposure Limits, ADC, Antibody Drug Conjugate, HPAPI, Highly Potent Active Pharmaceutical Ingredients, SMi Group, Pharmaceutical conferences, Pharma